Elicio Therapeutics, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANG)
CIK: 0001601485
Period of Report: 2021-02-04

Reporting Person: Neylan John F. (See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	38895	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$6.43	2028-12-18	Common Stock (116687)		Direct
Stock Option (Right to Buy)	$7.78	2030-06-17	Common Stock (93349)		Direct

Footnotes

F1: Reflects a 1-to-1.55583 stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2: Includes 38,895 Restricted Stock Awards ("RSAs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSA upon the vesting thereof.

F3: 25% of the total shares subject to the option shall vest on the first anniversary measured from December 17, 2018 (the "Vesting Commencement Date") and 1/24th of the shares subject to the option will vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date.

F4: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from June 18, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.